aladorian (ARM036) / Servier, RyCarma Therapeutics - LARVOL DELTA

Ryanodine Receptors Matter for Cardiac Function in Duchenne Muscular Dystrophy: Stability First. (PubMed, J Am Coll Cardiol) - No abstract available

Journal • Atrial Fibrillation • Cardiovascular • Duchenne Muscular Dystrophy • Genetic Disorders • Muscular Dystrophy

Stabilizing Ryanodine Receptors Improves Left Ventricular Function in Juvenile Dogs With Duchenne Muscular Dystrophy. (PubMed, J Am Coll Cardiol) - "GRMD-dogs exhibit early LV dysfunction associated with altered myofilament contractile properties. These abnormalities were prevented pharmacologically by stabilizing RyR2 with ARM036."

Journal • Cardiovascular • Congestive Heart Failure • Duchenne Muscular Dystrophy • Genetic Disorders • Heart Failure • Muscular Dystrophy

Macronutrient intakes and serum oestrogen, and interaction with polymorphisms in CYP19A1 and HSD17B1 genes: a cross-sectional study in postmenopausal Japanese women. (PubMed, Br J Nutr) - "...We documented dietary intakes, measured serum concentrations of oestrone (E1) and oestradiol (E2) and genotyped polymorphisms in oestrogen-metabolising CYP19A1 (rs4441215 and rs936306) and HSD17B1 (rs605059) genes...In stratified analysis by polymorphisms, the rs605059 genotype of HSD17B1 significantly modified associations of E2 with intake of n-3 HUFA and fish; the associations were limited to those with the CC genotype. Macronutrient intakes were associated with serum E2 level, and these associations may be modified by HSD17B1 polymorphism in postmenopausal women."

Journal • Biosimilar • Breast Cancer

PREDICTION OF RENAL OAT1 AND OAT3 INHIBITION BY CABOTEGRAVIR USING PBPK MODELLING (CROI 2019) - "...DDI simulations were performed to evaluate the effect of CAB oral doses on the exposure of OAT1/OAT3 substrates (methotrexate, tenofovir, ciprofloxacin, cidofovir, cefuroxime, oseltamivir carboxylate, baricitinib, and S44121). Simulated DDIs for above mentioned OAT1/OAT3 substrates and inhibitors (probenecid, diclofenac) were within two-fold of the observed clinical DDIs...Similar CAB concentrations following oral and LA administration suggest that these results would apply to CAB LA. The predicted lack of interactions supports co-administration with OAT1/OAT3 substrates without dose adjustments."